Pure Global AI
NCT06370754Not yet recruiting

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Fudan UniversityPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
JS001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 30, 2024
End date
Apr 30, 2027
Enrollment
117 participants
Primary outcome

Incidence of dose-limiting toxicity (DLT) (phase IB),Objective Response Rate (ORR) (phase II)

Summary

This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of
 different novel immunotherapies in patients with advanced pancreatic cancer.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06370754
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06370754 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Fudan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 117 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.